Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 31;39(37):5326-5330.
doi: 10.1016/j.vaccine.2021.06.081. Epub 2021 Jul 2.

Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification

Affiliations

Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification

Nimrod Rahamimov et al. Vaccine. .

Abstract

Background: Recent phase-3 clinical trials have demonstrated very encouraging results for mRNA based vaccines against COVID-19. Current FDA and manufacturer guidelines mandate intramuscular administration of these vaccines, as other administration routes may not provide the same levels of effectiveness and safety. Observing the vast amount of published media images of persons receiving their vaccines, the authors noted in many cases the injection technique involved skin bunching, raising concerns of inadequate deltoid muscle penetration and consequent lowered vaccine efficacy. Our study hypothesis was that skin bunching will increase the skin-to-muscle distance over 20 mm, the maximal distance allowing the required 5 mm muscle penetration with a 25 mm needle.

Materials and methods: 60 adult volunteers from our hospital staff were recruited, and using ultrasound, the skin-to-muscle distance measured in three positions: flat, skin bunching and muscle bunching. The skin-to-muscle distance difference and correlation with gender and BMI were calculated.

Results: Skin bunching significantly increased the skin-to-muscle distance in all subjects. In 6 (10%) subjects, this increase exceeded the 20 mm limit. Having a skin-to-deltoid distance of 20 mm or more strongly correlated with a BMI of 30 or more.

Conclusions: Skin bunching will prevent adequate intramuscular injection of vaccines in a small percentage of persons, but as hundreds of millions are expected to receive mRNA vaccines in the coming months, the multiplied result can have significant personal and societal consequences for millions of people globally, especially in obese populations, and therefore this practice should be strictly discouraged.

Keywords: COVID-19; Vaccine administration errors; mRNA vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Bunching of the skin during intramuscular vaccine administration, raising the question of appropriate depth of muscle penetration. Pictured: An Arizona National Guard soldier administers COVID-19 vaccine in Payson in Jan. 4th 2021 (Photo by Tech. Sgt. Michael Matkin, Arizona National Guard, Creative Commons copyright).
Fig. 2
Fig. 2
Skin markings for standard reference point (SRP).
Fig. 3
Fig. 3
Skin to muscle distance in subject A when the skin or muscle were not bunched. The overlaying copious amount of gel is clearly visualized demonstrating this measurement was done without the transducer exerting pressure on the skin.
Fig. 4
Fig. 4
Examination while skin bunching.
Fig. 5
Fig. 5
Skin to muscle distance in subject A when the skin is bunched. Although still within the acceptable range for proper IM needle penetration, skin bunching increased the distance by approximately 50%.

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920–1931. - PMC - PubMed
    1. Hassett K.J., Benenato K.E., Jacquinet E., Lee A., Woods A., Yuzhakov O., et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019;15:1–11. - PMC - PubMed
    1. CDC. Pfizer-BioNTech COVID-19 Vaccine administration. https://wwwcdcgov/vaccines/covid-19/info-by-product/pfizer/indexhtml.
    1. CDC. Moderna COVID-19 Vaccine. https://wwwcdcgov/vaccines/covid-19/info-by-product/moderna/indexhtml.